Capricor Therapeutics CAPR shares ended the last trading session 20.4% higher at $9.25. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the ...

Capricor (CAPR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down ...

CAPRICOR THERAPEUTICS INC (CAPR) is a small-cap value stock in the Biotechnology & Drugs industry. The rating using this strategy is 59% based on the firm’s underlying fundamentals and the stock ...

Below is Validea's guru fundamental report for CAPRICOR THERAPEUTICS INC (CAPR). Of the 22 guru strategies we follow, CAPR rates highest using our P/B Growth Investor model based on the published ...

Capricor Therapeutics' phase 3 trial completion is expected in 2023, with promising results and BLA submission in 2025. Learn more on CAPR stock here.